Published in
American Association for the Advancement of Science, Science Translational Medicine, 485(11), 2019
DOI: 10.1126/scitranslmed.aat3005
Links
Tools
A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy
Journal article published in 2019 by
Israel Hernandez 
,
Gabriel Luna,
Jennifer N. Rauch,
Surya A. Reis ,
Michel Giroux ,
Celeste M. Karch ,
Daniel Boctor,
Youssef E. Sibih ,
Nadia J. Storm,
Antonio Diaz,
Susmita Kaushik ,
Cezary Zekanowski,
Alexander A. Kang ,
Cassidy R. Hinman,
Vesna Cerovac
and other authors.
,
Gabriel Luna,
Jennifer N. Rauch,
Surya A. Reis ,
Michel Giroux ,
Celeste M. Karch ,
Daniel Boctor,
Youssef E. Sibih ,
Nadia J. Storm,
Antonio Diaz,
Susmita Kaushik ,
Cezary Zekanowski,
Alexander A. Kang ,
Cassidy R. Hinman,
Vesna Cerovac
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Targeting farnesylation of Rhes induces lysosomal-mediated tau degradation and reduces tau pathology in mice with tauopathy.